An understanding of the events that occur during GH receptor (GHR) signaling has
facilitated the development of a GHR antagonist (pegvisomant) for use in humans. This …

Radiolabelled meta-iodobenzylguanidine (MIBG) is widely used in the diagnosis, follow-up
and treatment of patients with tumours of neural crest origin. Some commonly prescribed …

Routine assessment of the hypothalamic–pituitary–adrenal axis relies on the measurement
of total serum cortisol levels. However, most cortisol in serum is bound to corticosteroid …

Background Patients with acromegaly are treated with surgery, radiation therapy, and drugs
to reduce hypersecretion of growth hormone, but the treatments may be ineffective and have …

Background Pegvisomant is a new growth hormone receptor antagonist that improves
symptoms and normalises insulin-like growth factor-1 (IGF-1) in a high proportion of patients …

Abstract Objective The European Registry on Cushing's syndrome (ERCUSYN) is designed
to collect prospective and follow-up data at EU level on Cushing's syndrome (CS). Design …

objective To analyse the clinical and biochemical effects of metyrapone in the treatment of
Cushing's syndrome. design An evaluation of the standard clinical practice at one institution …

The clinical, biochemical, and radiological features of pituitary ACTH-dependent Cushing's
syndrome (CS)[Cushing's disease (CD)] are often indistinguishable from those of occult …

OBJECTIVE We tested the hypothesis that in Cushing's disease, ACTH secretion from the
normal pituitary surrounding an ACTH‐secreting adenoma is inhibited and hence removal of …

Background: Cushing's syndrome (CS) is a severe condition with excess mortality and
significant morbidity necessitating control of hypercortisolemia. There are few data …